News Archives - Page 650 of 1253

WednesdayJan 13, 2021 11:02 am

NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Imagin Medical. Like most companies during 2020, Imagin had to adapt to the unexpected circumstances surrounding…

WednesdayJan 13, 2021 10:54 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Subsidiary, Eye-Net, Partners with Japanese Vehicle Manufacturer for Pilot Project

Foresight Autonomous (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision, announced that its wholly owned subsidiary, Eye-Net Mobile Ltd., is working with the intelligent transport system division of a multibillion-dollar global Japanese vehicle manufacturer to test the Eye-Net(TM) Protect cellular-based V2X (vehicle-to-everything) (“V2X”) accident-prevention solution. The pilot test project is designed to analyze and validate the software development kit (“SDK”) configuration of the Eye-Net solution for possible addition into a smart city project conducted by the vehicle manufacturer. The recently announced pilot test project follows Eye-Net’s August 2020 announcements regarding two additional pilot projects. Eye-Net is partnering with leading…

WednesdayJan 13, 2021 10:32 am

NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario's technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario's DTx (“DTx”) platform by integrating members' comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized…

WednesdayJan 13, 2021 10:07 am

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million in gross proceeds from the offering. In a concurrent private placement, Predictive Oncology also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of $0.80 per share. H.C. Wainwright & Co.…

WednesdayJan 13, 2021 9:46 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA approval to begin clinical trials studying the company’s lead drug candidate, Berubicin. CNSP is developing Berubicin as a potential treatment for glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Climaco called Berubicin…

WednesdayJan 13, 2021 9:20 am

NetworkNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Secures $5.1M in Underwritten Public Offering

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial metal 3D printing industry, has announced the closing of its previously disclosed underwritten public offering of 1,488,507 shares of common stock, each at a public offering price of $3.00. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 223,276 shares of common stock at the public offering price, less the underwriting discount. Sigma Labs secured $5,135,349 in gross proceeds from the offering consisting of 1,711,783 shares. H.C. Wainwright & Co. acted as the sole book-running manager for the…

TuesdayJan 12, 2021 12:08 pm

NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Announces Strategic Engagements

Kaival Brands (OTCQB: KAVL), a company focused on generating stockholder value by incubating innovative products into mature and dominant brands within their respective markets, today announced new engagements of both Morgan Lewis and Spencer Stuart. According to the update, the company believes that these engagements will allow it to continue its expansion and assist in reaching its next iterative stage of growth. “We have enjoyed tremendous revenue growth in a rapid fashion,” said CEO Niraj Patel. “We are now in a position to build the appropriate infrastructure to match our current and aspirational revenue targets.” To view the full press…

TuesdayJan 12, 2021 11:47 am

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers use of niclosamide as a treatment for COVID-19-associated GI disease. AZRX filed the patent with First Wave, a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions. GI infections have become a significant unmet clinical need during the…

TuesdayJan 12, 2021 11:22 am

NetworkNewsBreaks – PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) Hires Jon Lamb to Serve as President of North American Operations

PowerBand Solutions (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA), an innovative automotive fintech leader providing digital and virtual platform solutions, today announced the appointment of Jon Lamb to one of the company's top executive leadership roles as president of North American Operations. Lamb has founded and served as CEO and president of numerous successful business entities and is a patent author and mission-driven investor. Jon serves as an active board member and advisor to multiple ad tech and fintech organizations. "Filling the critical role of president of North American operations was a major decision for the company,” said Kelly Jennings, CEO…

TuesdayJan 12, 2021 11:01 am

NetworkNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Becomes One of First Publicly Traded Companies to Receive USDA Organic Certification for CBD Tinctures

HempFusion Wellness (TSX: CBD.U), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has received USDA Organic Certification for its HempFusion CBD tinctures; the exclusive line of tinctures offers products with potency from 150mg (5mg per serving) to 1,500mg (50mg per serving) of CBD per bottle. HempFusion is one of the first publicly traded CBD companies to receive the certification; the distinction is significant because organic products generally represent some of the highest quality products available. The process to certify its tinctures as USDA Organic started in 2018, and involve providing detailed documentation for every…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Breaks Categories: News